|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Beltran A, Carrasco JC, Cheng L,
Scarpelli M, Kirkali Z and Montironi R: 2009 update on the
classification of renal epithelial tumors in adults. Int J Urol.
16:432–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rini BI, Campbell SC and Rathmell WK:
Renal cell carcinoma. Curr Opin Oncol. 18:289–296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugawara E, Togashi Y, Kuroda N, Sakata S,
Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, et al:
Identification of anaplastic lymphoma kinase fusions in renal
cancer: Large-scale immunohistochemical screening by the
intercalated antibody-enhanced polymer method. Cancer.
118:4427–4436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pécuchet N, Fournier LS and Oudard S: New
insights into the management of renal cell cancer. Oncology.
84:22–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singer EA, Gupta GN and Srinivasan R:
Targeted therapeutic strategies for the management of renal cell
carcinoma. Curr Opin Oncol. 24:284–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morris SW, Kirstein MN, Valentine MB,
Dittmer KG, Shapiro DN, Saltman DL and Look AT: Fusion of a kinase
gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's
lymphoma. Science. 263:1281–1284. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lawrence B, Perez-Atayde A, Hibbard MK,
Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher
CD and Fletcher JA: TPM3-ALK and TPM4-ALK oncogenes in inflammatory
myofibroblastic tumors. Am J Pathol. 157:377–384. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren H, Tan ZP, Zhu X, Crosby K, Haack H,
Ren JM, Beausoleil S, Moritz A, Innocenti G, Rush J, et al:
Identification of anaplastic lymphoma kinase as a potential
therapeutic target in ovarian cancer. Cancer Res. 72:3312–3323.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mossé YP, Laudenslager M, Longo L, Cole
KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P,
et al: Identification of ALK as a major familial neuroblastoma
predisposition gene. Nature. 455:930–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janoueix-Lerosey I, Lequin D, Brugières L,
Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A,
Schleiermacher G, Pierron G, et al: Somatic and germline activating
mutations of the ALK kinase receptor in neuroblastoma. Nature.
455:967–970. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
George RE, Sanda T, Hanna M, Fröhling S,
Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al:
Activating mutations in ALK provide a therapeutic target in
neuroblastoma. Nature. 455:975–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Takita J, Choi YL, Kato M, Ohira
M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al:
Oncogenic mutations of ALK kinase in neuroblastoma. Nature.
455:971–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murugan AK and Xing M: Anaplastic thyroid
cancers harbor novel oncogenic mutations of the ALK gene. Cancer
Res. 71:4403–4411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tuma RS: ALK gene amplified in most
inflammatory breast cancers. J Natl Cancer Inst. 104:87–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schoppmann SF, Streubel B and Birner P:
Amplification but not translocation of anaplastic lymphoma kinase
is a frequent event in oesophageal cancer. Eur J Cancer.
49:1876–1881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mano H: ALKoma: A cancer subtype with a
shared target. Cancer Discov. 2:495–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gambacorti-Passerini C, Messa C and
Pogliani EM: Crizotinib in anaplastic large-cell lymphoma. N Engl J
Med. 364:775–776. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mossé YP, Lim MS, Voss SD, Wilner K,
Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ,
et al: Safety and activity of crizotinib for paediatric patients
with refractory solid tumours or anaplastic large-cell lymphoma: A
Children's Oncology Group phase 1 consortium study. Lancet Oncol.
14:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Butrynski JE, D'Adamo DR, Hornick JL, Dal
Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ,
Ramaiya N, et al: Crizotinib in ALK-rearranged inflammatory
myofibroblastic tumor. N Engl J Med. 363:1727–1733. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong KM, Noonan S, O'Bryant C and Jimeno
A: Alectinib for the treatment of ALK-positive stage IV non-small
cell lung cancer. Drugs Today (Barc). 51:161–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loong HH, Mok K, Leung LK and Mok TS:
Crizotinib in the management of advanced-stage non-small-cell lung
cancer. Future Oncol. 11:735–745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Debelenko LV, Raimondi SC, Daw N,
Shivakumar BR, Huang D, Nelson M and Bridge JA: Renal cell
carcinoma with novel VCL-ALK fusion: New representative of
ALK-associated tumor spectrum. Mod Pathol. 24:430–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mariño-Enríquez A, Ou WB, Weldon CB,
Fletcher JA and Pérez-Atayde AR: ALK rearrangement in sickle cell
trait-associated renal medullary carcinoma. Genes Chromosomes
Cancer. 50:146–153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smith NE, Deyrup AT, Mariño-Enriquez A,
Fletcher JA, Bridge JA, Illei PB, Netto GJ and Argani P: VCL-ALK
renal cell carcinoma in children with sickle-cell trait: The eighth
sickle-cell nephropathy? Am J Surg Pathol. 38:858–863. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sukov WR, Hodge JC, Lohse CM, Akre MK,
Leibovich BC, Thompson RH and Cheville JC: ALK alterations in adult
renal cell carcinoma: Frequency, clinicopathologic features and
outcome in a large series of consecutively treated patients. Mod
Pathol. 25:1516–1525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hodge JC, Pearce KE and Sukov WR: Distinct
ALK-rearranged and VCL-negative papillary renal cell carcinoma
variant in two adults without sickle cell trait. Mod Pathol.
26:604–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee C, Park JW, Suh JH, Nam KH and Moon
KC: ALK-positive renal cell carcinoma in a large series of
consecutively resected Korean renal cell carcinoma patients. Korean
J Pathol. 47:452–457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie S, Li Y, Li X, Wang L, Yang N, Wang Y
and Wei H: Mer receptor tyrosine kinase is frequently overexpressed
in human non-small cell lung cancer, confirming resistance to
erlotinib. Oncotarget. 6:9206–9219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang X, Zhang S, Yang X, Yang J, Zhou Q,
Yin L, An S, Lin J, Chen S, Xie Z, et al: Fusion of EML4 and ALK is
associated with development of lung adenocarcinomas lacking EGFR
and KRAS mutations and is correlated with ALK expression. Mol
Cancer. 9:1882010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mino-Kenudson M, Chirieac LR, Law K,
Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA,
Iafrate AJ and Rodig SJ: A novel, highly sensitive antibody allows
for the routine detection of ALK-rearranged lung adenocarcinomas by
standard immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roskoski R Jr: Anaplastic lymphoma kinase
(ALK): Structure, oncogenic activation, and pharmacological
inhibition. Pharmacol Res. 68:68–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Debelenko LV: Reply to ‘Distinct
ALK-rearranged and VCL-negative papillary renal cell carcinoma
variants in two adults without sickle cell trait’. Mod Pathol.
26:605–607. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuroda N, Sugawara E, Kusano H, Yuba Y,
Yorita K and Takeuchi K: A review of ALK-rearranged renal cell
carcinomas with a focus on clinical and pathobiological aspects.
Pol J Pathol. 69:109–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
